Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUTLNYSE:DNANASDAQ:ERYPNASDAQ:SANA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.33-5.0%$1.63$1.11▼$5.00$353.91M2.061.47 million shs2.74 million shsDNAGinkgo Bioworks$7.85-0.3%$7.62$5.00▼$45.20$456.73M1.341.49 million shs648,414 shsERYPERYTECH Pharma$3.10$4.66$0.30▼$1.47$105.77M2.6993,510 shsN/ASANASana Biotechnology$1.77$2.12$1.26▼$10.50$398.29M1.783.30 million shs2.30 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics-7.28%-2.10%-13.58%-40.93%-66.75%DNAGinkgo Bioworks+3.95%+0.70%+10.35%-38.17%-83.00%ERYPERYTECH Pharma0.00%0.00%0.00%0.00%0.00%SANASana Biotechnology+3.81%+7.27%-17.67%-47.63%-79.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUTLAutolus Therapeutics2.4347 of 5 stars3.51.00.00.02.63.30.6DNAGinkgo Bioworks0.6224 of 5 stars0.81.00.00.01.82.51.3ERYPERYTECH PharmaN/AN/AN/AN/AN/AN/AN/AN/ASANASana Biotechnology2.2611 of 5 stars3.41.00.00.02.23.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics 3.00Buy$9.32600.75% UpsideDNAGinkgo Bioworks 1.60Reduce$4.58-41.72% DownsideERYPERYTECH Pharma 0.00N/AN/AN/ASANASana Biotechnology 2.86Moderate Buy$10.80510.17% UpsideCurrent Analyst Ratings BreakdownLatest ERYP, DNA, AUTL, and SANA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2025SANASana BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.004/10/2025AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/1/2025AUTLAutolus TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/21/2025AUTLAutolus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$8.00 ➝ $6.003/18/2025SANASana BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/18/2025SANASana BiotechnologyCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$5.003/14/2025SANASana BiotechnologyJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$7.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$10.12M34.97N/AN/A$0.64 per share2.08DNAGinkgo Bioworks$227.04M2.01N/AN/A$21.93 per share0.36ERYPERYTECH Pharma$32.66M3.24N/AN/A$0.80 per share3.88SANASana BiotechnologyN/AN/AN/AN/A$1.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$208.38M-$0.86N/AN/AN/AN/A-63.65%-36.54%5/8/2025 (Estimated)DNAGinkgo Bioworks-$892.87M-$10.68N/AN/AN/A-298.78%-58.54%-34.24%5/8/2025 (Estimated)ERYPERYTECH Pharma-$240KN/A0.00∞N/AN/AN/AN/AN/ASANASana Biotechnology-$283.26M-$1.16N/AN/AN/AN/A-84.22%-44.97%5/6/2025 (Estimated)Latest ERYP, DNA, AUTL, and SANA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SANASana Biotechnology-$0.22N/AN/AN/AN/AN/A5/8/2025Q1 2025AUTLAutolus Therapeutics-$0.24N/AN/AN/A$1.59 millionN/A5/8/2025Q1 2025DNAGinkgo Bioworks-$1.23N/AN/AN/AN/AN/A3/20/2025Q4 2024AUTLAutolus Therapeutics-$0.21-$0.09+$0.12-$0.09$2.98 million$0.03 million3/17/2025Q4 2024SANASana Biotechnology-$0.25-$0.23+$0.02-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/AERYPERYTECH PharmaN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A13.6913.69DNAGinkgo BioworksN/A5.795.79ERYPERYTECH Pharma0.323.653.65SANASana BiotechnologyN/A4.474.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%DNAGinkgo Bioworks78.63%ERYPERYTECH Pharma1.09%SANASana Biotechnology88.23%Insider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%DNAGinkgo Bioworks9.72%ERYPERYTECH Pharma1.94%SANASana Biotechnology31.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics330266.09 million197.71 millionOptionableDNAGinkgo Bioworks64058.03 million51.89 millionOptionableERYPERYTECH Pharma4934.12 million33.46 millionNot OptionableSANASana Biotechnology380225.03 million153.83 millionOptionableERYP, DNA, AUTL, and SANA HeadlinesRecent News About These CompaniesLost Money on Sana Biotechnology, Inc. (SANA)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyApril 25 at 3:45 PM | accessnewswire.comSANA Investors Have the Opportunity to Lead the Sana Biotechnology Securities Fraud Lawsuit with Faruqi & Faruqi, LLPApril 25 at 3:16 PM | accessnewswire.comLevi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SANAApril 25 at 11:30 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers – SANAApril 25 at 10:56 AM | globenewswire.comLevi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sana Biotechnology, Inc. (SANA) ShareholdersApril 25 at 7:15 AM | accessnewswire.comSANA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!April 25 at 7:00 AM | accessnewswire.comContact Levi & Korsinsky by May 20, 2025 Deadline to Join Class Action Against Sana Biotechnology, Inc.(SANA)April 25 at 5:45 AM | prnewswire.comSANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineApril 25 at 12:30 AM | accessnewswire.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANAApril 24 at 8:13 PM | accessnewswire.comWhy Sana Biotechnology, Inc.’s (SANA) Stock Is Up 7.80%April 24 at 4:19 PM | aaii.comContact Levi & Korsinsky by May 20, 2025 Deadline to Join Class Action Against Sana Biotechnology, Inc. (SANA)April 24 at 2:15 PM | accessnewswire.comContact Levi & Korsinsky by May 20, 2025 Deadline to Join Class Action Against Sana Biotechnology, Inc. (SANA)April 24 at 2:15 PM | accessnewswire.comLevi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 – SANAApril 24 at 12:24 PM | globenewswire.comSana Biotechnology, Inc. Class Action: Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANAApril 24 at 10:55 AM | accessnewswire.comSANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law FirmApril 24 at 10:32 AM | prnewswire.comLevi & Korsinsky Notifies Shareholders of Sana Biotechnology, Inc. (SANA) of a Class Action Lawsuit and an Upcoming DeadlineApril 24 at 8:30 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANAApril 24 at 8:00 AM | accessnewswire.comClass Action Filed Against Sana Biotechnology, Inc. (SANA) Seeking Recovery for Investors - Contact Levi & KorsinskyApril 24 at 7:25 AM | accessnewswire.comSANA Shareholders Have Opportunity to Lead Sana Biotechnology, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!April 24 at 7:00 AM | accessnewswire.comShareholders that lost money on Sana Biotechnology, Inc. ...April 24 at 6:41 AM | gurufocus.comSana Biotechnology, Inc. (NASDAQ:SANA) Shares Sold by Vanguard Group Inc.April 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeERYP, DNA, AUTL, and SANA Company DescriptionsAutolus Therapeutics NASDAQ:AUTL$1.33 -0.07 (-5.00%) Closing price 04:00 PM EasternExtended Trading$1.34 +0.01 (+0.75%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Ginkgo Bioworks NYSE:DNA$7.85 -0.02 (-0.25%) Closing price 03:59 PM EasternExtended Trading$7.90 +0.05 (+0.65%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.ERYTECH Pharma NASDAQ:ERYPERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.Sana Biotechnology NASDAQ:SANA$1.77 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.78 +0.01 (+0.85%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
